Agoraphobia: relative and combined effectiveness of therapist-assisted in vivo exposure and imipramine.
Sixty-two chronically agoraphobic patients completed a controlled study to assess the effects of 1) imipramine up to 200 mg/day (mean = 130 mg/day), 2) 12 weekly therapist-assisted in vivo exposure sessions (flooding), and 3) imipramine plus flooding. The control group received systematic therapeutic instructions for self-directed in vivo exposure (programmed practice). Clinical measures of global severity, phobia, panic, anxiety, depression, and behavioral performance tests were administered before treatment and at Weeks 4, 8, and 12 of treatment. Results revealed significant improvement in all groups on all measures over the course of treatment; almost a third of the control patients showed marked improvement. Imipramine had significant effects on improvement of phobias and markedly increased clinical response rates in patients receiving 150-200 mg/day. Less chronicity and severity of condition also predicted better clinical outcome. Flooding had limited effects above and beyond programmed practice, and no imipramine-flooding interactions effects were found.
D000328:Adult; D000379:Agoraphobia / Q000188:drug therapy / Q000523:psychology / Q000628:therapy*; D001008:Anxiety Disorders / Q000188:drug therapy / Q000523:psychology / Q000628:therapy; D001521:Behavior Therapy; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use*; D007171:Implosive Therapy; D008297:Male; D010200:Panic; D010698:Phobic Disorders / Q000628:therapy*; D010919:Placebos; D011569:Psychiatric Status Rating Scales
D010919:Placebos; D007099:Imipramine